Mylan NV has been overcharging the U.S. for years on its EpiPen allergy shot, a government agency said, as two lawmakers said the company was “bilking” taxpayers and may have made billions by misclassifying the drug under complex Medicaid pricing rules.
In a letter to a U.S. senator Wednesday, the Centers for Medicare and Medicaid Services, or CMS, said Mylan for years overcharged the health program for the poor. Since 1997, EpiPen has been wrongly classified as a generic treatment, which has let Mylan pay lower discounts than the program requires for brand-name drugs. Mylan, which acquired EpiPen in 2007, denies it acted improperly.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
